Publication: 2760

Comparison of Residual Cancer Burden, American Joint Committee on Cancer staging and Pathologic Complete Response in Breast Cancer after Neoadjuvant Chemotherapy: Results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)
      QxMD      Google Scholar   
Citation:
Breast Cancer Res Treat vol 165 (1) 181-191
Year:
2017
Type:
Manuscript
Funding:
NCTN
Endpoint:
Secondary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
pmc-release
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
6
Parents:
None
Children:
None
Program:
OGC
Primary Committee:
Breast
Sec. Committees:
   
Pharmas:
 
Grants:
U10CA180821 , U01 CA111234, U01 CA080098, U10 CA031946, U10 CA033601, U10 CA180821, U10 CA077597, U10 CA079778, P50 CA058207, U10 CA041287, U01 CA079778, U10 CA047559, U10 CA077651, P01 CA210961, U10 CA080098, U10 CA180838  
Corr. Author:
 
Authors:
                               
Networks:
 
Study
CALGB-150007
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
N/A
Keywords:
Breast neoplasm, neoadjuvant therapy, local neoplasm recurrence, residual neoplasm, cancer staging, lymph nodes, disease-free survival, lymph nodes, Residual Cancer Burden, pathologic complete response